Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Vvd-130850
Cancer
Vividion Therapeutics, Inc.
P1
C
(36)
Vvd-133214
Cancer
Vividion Therapeutics, Inc.
P1
C
(36)
Vvd-159642
Cancer
Vividion Therapeutics, Inc.
P1
C
(36)
Wgi-0301
Cancer
Zhejiang Haichang Biotech Co., Ltd.
P1
C
(36)
wj01024
Cancer
Suzhou Junjing BioSciences Co., Ltd.
P1
C
(36)
wj01075
Cancer
Suzhou Junjing BioSciences Co., Ltd.
P1
C
(36)
Wsk-Im02
Cancer
WestVac Biopharma Co., Ltd.
P1
C
(36)
yl211
Cancer
MediLink Therapeutics (Suzhou) Co., Ltd.
P1
C
(36)
zw191
Cancer
Zymeworks BC Inc.
P1
C
(36)
zx-8177
Cancer
Nanjing Zenshine Pharmaceuticals
P1
C
(36)
Debio 0123
Cancer
Debiopharm International SA
P1
C
(33)
177lu-rad202
Cancer
Radiopharm Theranostics, Ltd
Early P1
C
(33)
Amt-676
Cancer
Multitude Therapeutics Inc.
Early P1
C
(33)
Anti-Car-Nk Cells
Cancer
Wuxi People's Hospital
Early P1
C
(33)
b7h3 car-γδt cells
Cancer
Peking University
Early P1
C
(33)
Car-Dc
Cancer
Peking University Shenzhen Hospital
Early P1
C
(33)
im92 car-t cells
Cancer
Beijing Immunochina Medical Science & Technology Co., Ltd.
Early P1
C
(33)
im96 car-t cells
Cancer
Beijing Immunochina Medical Science & Technology Co., Ltd.
Early P1
C
(33)
Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-Til)
Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Early P1
C
(33)
nk521 cell
Cancer
Base Therapeutics (Shanghai) Co., Ltd.
Early P1
C
(33)
Saprna™-Mica/B Tumor Vaccine
Cancer
NING LI
Early P1
C
(33)
gt307
Cancer
Grit Biotechnology
N/A
D
(26)
Pegylated Interferon Α-2B
Cancer
The First Affiliated Hospital of Xiamen University
N/A
D
(26)
Trotabresib
Cancer
Bristol-Myers Squibb
P1
D
(21)
cs5007
Cancer
CStone Pharmaceuticals
P1
NR
(0)
Showing 376 to 400 of 423 assets
Previous
Page 16 of 17
Next
